In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...
Read MoreType(s) of chemotherapy-Single drug-Capecitabine Posts on Medivizor
Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain
In a nutshell This study looked at treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases (BM) with tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine (Xeloda). This study found that this treatment reduces the risk of cancer worsening in these...
Read MorePredicting response to lapatinib therapy in HER2 positive breast cancer
In a nutshell This study investigated predictors of response to therapy in patients with HER2-positive advanced breast cancer. The study concluded that mucocutaneous toxicities (those affecting the skin or mucous membranes) could be predictors of the response to lapatinib (Tykerb or Tyverb) in patients with HER2-positive advanced breast...
Read MoreEvaluating the addition of Capecitabine to postoperative standard chemotherapy
In a nutshell This article presents summarized data from two clinical trials. The trials evaluated the addition of Capecitabine to standard postoperative chemotherapy for patients with high risk early breast cancer. Some background Capecitabine is a chemotherapy drug that is taken orally and slows the growth of tumors. It can be...
Read More